2026-01-13 - Analysis Report
**Eli Lilly and Co (LLY) Report**
================================

**Simple Numbers**
-----------------

* Cumulative return: 281.90%
* S&P 500 cumulative return: 94.34%
* Divergence: 181.70
* Relative divergence: 80.50%
* 5-day SMA: $1,080.38
* 20-day SMA: $1,068.69
* 60-day SMA: $992.54
* Close: $1,081.00
* Last-market change: $18.44 (1.64%)
* RSI: 52.44
* PPO: -0.29
* Hybrid Signal: Buy (Cash 0%)
* Risk Level: Medium (MRI 0.80)
* Expected Return: 52.10%
* Market Risk Indicator (MRI): 0.80
* Current Analyst Consensus (Buy/Sell rating):
  - Key: Buy
  - Mean (1=StrongBuy~5=Sell): 1.70 (~Buy)
  - Opinions: 27
  - Target Price (avg/high/low): $1116.33 / $1500.00 / $770.00
* Latest earnings: Q42025 - EPS: $6.22, Revenue: $17.60B
* Analyst Opinions: (printed exactly as-is)
  - Analyst Consensus:
  - Key: Buy
  - Mean (1=StrongBuy~5=Sell): 1.70 (~Buy)
  - Opinions: 27
  - Target Price (avg/high/low): 1116.33 / 1500.00 / 770.00

**Analysis**
------------

1. The return rate of Eli Lilly and Co (LLY) far exceeds that of the S&P 500, with a cumulative return of 281.90% compared to 94.34% for the S&P 500. This indicates a high level of divergence between the two, with a difference of 181.70.
2. The 5-day SMA, 20-day SMA, and 60-day SMA are $1,080.38, $1,068.69, and $992.54, respectively. The current stock price of $1,081.00 is between the 5-day SMA and 20-day SMA.
3. The RSI is at 52.44, which is not in overbought territory.
4. The PPO is -0.29, indicating a downward trend.
5. The Hybrid Signal is Buy (Cash 0%) with a risk level of Medium.
6. The Market Risk Indicator (MRI) is at 0.80, indicating a medium level of risk.
7. The Expected Return is at 52.10%, which is high.
8. The latest earnings analysis shows an increasing trend with Q42025 EPS at $6.22 and revenue at $17.60B.

**Recent News & Significant Events**
--------------------------------------

Recent news highlights Eli Lilly's recent breakout and interest in Ventyx Biosciences, as well as a French biotech stock surging 1,700% in 2025. Additionally, analyst opinions are mixed with a consensus rating of Buy.

**Recent Earnings Analysis**
---------------------------

| Date | EPS | Revenue |
|------|-----|----------|
| 2025-10-30 | $6.22 | $17.60 B |
| 2025-08-07 | $6.3 | $15.56 B |
| 2025-05-01 | $3.07 | $12.73 B |
| 2024-10-30 | $1.08 | $11.44 B |
| 2025-10-30 | $1.08 | $11.44 B |

The latest earnings analysis shows an increasing trend with Q42025 EPS at $6.22 and revenue at $17.60B.

**Revenue and Profitability**
---------------------------

| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2025-09-30 | $17.60B | 82.91% |
| 2025-06-30 | $15.56B | 84.27% |
| 2025-03-31 | $12.73B | 82.53% |
| 2024-12-31 | $13.53B | 82.24% |
| 2024-09-30 | $11.44B | 81.02% |

The revenue and profit margin analysis shows a stable trend with a slight increase in profit margin in recent quarters.

**Capital and Profitability**
---------------------------

| Quarter | Equity | ROE |
|---------|---------|-----|
| 2025-09-30 | $23.79B | 23.46% |
| 2025-06-30 | $18.27B | 30.98% |
| 2025-03-31 | $15.76B | 17.50% |
| 2024-12-31 | $14.19B | 31.07% |
| 2024-09-30 | $14.24B | 6.81% |

The capital and profitability analysis shows an increasing trend in ROE in recent quarters.

**Comprehensive Analysis (Summary)**
--------------------------------------

Overall, the analysis highlights Eli Lilly and Co's (LLY) strong performance, including a high cumulative return, increasing EPS, and stable revenue. However, the current PPO indicator suggests a downward trend. Additionally, the risk level is classified as medium, which may be a concern for investors.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.